Afexa Life Sciences Inc.

Afexa Life Sciences Inc.

October 17, 2005 06:00 ET

Business Update: CV Technologies Inc.-Makers of COLD-fX'R'-Inks Partnership Deal with the Montreal Canadiens as part of the Company's Expansion into Quebec.

MONTREAL, QUEBEC--(CCNMatthews - Oct. 17, 2005) - CV Technologies Inc. (CVT) (TSX VENTURE:CVQ) today announced it has signed a partnership agreement with the Montreal Canadiens as part of the Company's product launch into Quebec.

Les Canadiens have relied on COLD-fX® for the past five seasons to help protect the team during cold and flu season. Now, based on COLD-fX's effectiveness at keeping the team healthy, and in celebration of the Company's newly announced expansion in Quebec, COLD-fX ® moves officially onto the blue, white and red bench, as the trusted cold and flu remedy of the Montreal Canadiens.

"The Montreal Canadiens have used COLD-fX® with confidence for years," confirms team head athletic therapist Graham Rynbend, adding that he has given the team COLD-fX® before they get their annual flu shots for added protection as well as throughout the season. "Our players are traveling, they are in crowded arenas, so colds and flu are a major issue that we deal with as therapists. COLD-fX® works for us because it's natural and it doesn't just treat the symptoms - it actually helps prevent colds and flu."

COLD-fX® has been used over the years by athletic therapists, trainers and players of 26 professional hockey teams and Canada's elite athletes, including Quebec resident, gold medalist and world champion speed skater and cyclist Clara Hughes. Hughes is one of 150 athletes training for the 2006 Torino games who rely on it to keep them healthy.

CVT CEO & Chief Scientific Officer, Dr. Jacqueline Shan said, "Our Company owes a significant measure of its commercial success to its connection with the athletic world. Given our long history with the Canadiens, it was a natural partnership to mark and celebrate our new phase of growth in Quebec."

"Quebecers are advanced, discriminating and very educated when it comes to selecting quality alternative and complementary medicine," explains Dr. Shan. "That's why we're investing in the Quebec community. We want to thank Quebecers for their support, and celebrate the fact that COLD-fX® is now available in specialty and major retailers across the province

In addition to sponsorships and increased retail distribution, COLD-fX® plans to launch a new advertising campaign later this month that's been custom-created for the Quebec market in collaboration with a Montreal-based ad agency.

COLD-fX® is available at pharmacies throughout the province including Jean Coutu, Pharmaprix, Familprix, Uniprix, Costco, Le Comptoir -Wal-Mart, Groupe Essaim, Le Naturiste, Brunet, Metro, McMahon Distributors, Zellers and Provigo.


CV Technologies was founded in 1992. It aims to become a global leader in the development and commercialization of evidence based, natural medicines for disease prevention and health maintenance. CVT's lead product - COLD-fX®, - the top selling cold remedy in Canada according to ACNielsen, strengthens the immune system and is widely used as a leading anti-cold, anti-flu, non-prescription treatment. COLD-fX's unique, patented, mechanism of action was developed and standardized according to the Company's ChemBioPrint (CBP™) technology. The CBP™ process precisely identifies the chemical profile and biological activity of multi-active components in natural compounds. The CBP™ process provides a manufacturing protocol that ensures each batch of compound delivers verifiable and provable health benefits.

This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "expects" and similar expressions are intended to identify forward-looking statements. Such risks and uncertainties include, but are not limited to, the need for capital, changing market conditions, completion of clinical trials, patient enrolment rates, uncertainty of pre-clinical, retrospective and early clinical trial results, the establishment of manufacturing processes and new corporate alliances, the timely development, regulatory approval and market acceptance of the Company's products, and other risks detailed from time to time in the Company's filings with Canadian securities authorities.

Contact Information